QUOTE AND NEWS
Motley Fool  Apr 12  Comment 
I visited with top management and scientists at synthetic biology pioneer Amyris. Here are several insights for investors.
Motley Fool  Mar 2  Comment 
Oil prices are falling, but that hasn't stopped Brazil from working toward cleaning the environment and boosting its own economy.
Motley Fool  Feb 28  Comment 
Amyris has a steadily increasing stream of momentum behind it as the next-generation biotech enters 2015.
Biomass Magazine  Feb 26  Comment 
Amyris Inc. has released financial results for 2014. During an investor call, John Melo, president and CEO of the company, called 2014 a transformative year for Amyris, noting the company manufactured two breakthrough molecules at industrial scale.
Motley Fool  Jan 31  Comment 
Amyris is an intriguing pick for anyone's favorite stock, so here are some risks to keep in mind.
Benzinga  Jan 21  Comment 
McDermott International Inc. (NYSE: MDR) shares touched a new 52-week low of $2.145. UBS downgraded McDermott from Buy to Neutral. Forestar Group Inc. (NYSE: FOR) shares tumbled 3.73% to reach a new 52-week low of $13.69. Forestar Group shares...
Biomass Magazine  Jan 21  Comment 
Amyris Inc. has announced it plans to launch its first industrial cleaning products containing Amyris's Myralene renewable solvents through U.S. AutoForce and U.S. Lubricants, divisions of U.S. Venture Inc.




 
TOP CONTRIBUTORS

Amyris Biotechnologies (NASDAQ:AMRS) creates, sells, and distributes renewable products that replace chemicals and fuels made from petroleum. Amyris genetically modifies yeast cells to ferment feedstocks into a series of different target molecules. The company then sells these target molecules to replace additives or fuels which are made from petroleum. The company originally focused on using sugar cane stalks and turned them into farnesene which is key additive in detergents, cosmetics, and transportable fuels among other things. Amyris has continued to diversify both the inputs it can take and the output molecules it can produce. Amyris has pushed to make its products competitive, both in price and effectiveness of replacement, even if they are renewable.[1]

Amyris currently does not have any commercial level efforts in place. It has only established a test facility next to its laboratories in California. The company hopes to expand to commercial distribution levels during 2011 by establishing contracts with sugar cane mills in Brazil. The company has agreed through a letter of intent with a large Brazilian manufacturer to establish a joint venture facility which would turn 10% of their sugar cane into farnesene.[2] The company has also entered into commercialization agreements with large chemical and cosmetic companies such as Procter & Gamble Company (PG).[3]

The company's initial public offering of stock filed on the NASDAQ and went public on the 27 of September 2010. It priced at $16, which was well below the initial price range of $18-$20. The company raised $85M by offering 5.3M shares. The lead underwriter of the deal were J P Morgan Chase (JPM), Morgan Stanley (MS), and Goldman Sachs Group (GS).[4]

Despite not producing at commercial levels, the company has achieved a net revenue for 2009 of $65M. However, due to the high Research & Development costs associated to its developmental stage, it incurred a net loss of $64M.[5]

References

  1. AMRS S-1/A 2010 "Our Company" pg 1
  2. AMRS S-1/A 2010 "Commercial Production" pg 2
  3. AMRS S-1/A 2010 "Commercialization and Distribution" pg 2
  4. Renaissance Capital - IPO "Amyris Biotechnologies prices IPO at $16, below the proposed range" 28 Sept 2010
  5. AMRS S-1/A 2010 "SUMMARY CONSOLIDATED FINANCIAL DATA" pg 10
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki